Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Embla Medical hfOSSFF 92 Cash-to-Debt is 0.19 as of Jun. 2026, which is 6% above its 10-year median of 0.18. GuruFocus rates OSSFF with a GF Score™ of 92/100 and a GF Value™ of $4.90. Among 849 Medical Devices & Instruments companies, Embla Medical hf ranks worse than 85.75% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Embla Medical hf's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.19.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Embla Medical hfcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Embla Medical hf's Cash-to-Debt or its related term are showing as below:
OSSFF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1 Med: 0.18 Max: 0.31
Current: 0.19
During the past 13 years, Embla Medical hf's highest Cash to Debt Ratio was 0.31. The lowest was 0.10. And the median was 0.18.
OSSFF's Cash-to-Debt is ranked worse than 85.75% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs OSSFF: 0.19
Embla Medical hf (OTCPK:OSSFF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Embla Medical hf Cash-to-Debt Related Terms
Embla Medical hf Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Embla Medical hf's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embla Medical hf (OSSFF) has a Cash-to-Debt of 0.19 as of Jun. 2026. This is near median its historical median of 0.18. Over the past decade, Embla Medical hf's Cash-to-Debt has ranged from 0.10 to 0.31. According to the industry distribution chart, Embla Medical hf ranks #728 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 85.7%.
Is Embla Medical hf's Cash-to-Debt too high?
Embla Medical hf's current Cash-to-Debt of 0.19 is near median its 10-year median of 0.18. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 0.31. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Embla Medical hf's value of 0.19 is 88.4% below this industry median. Based on the distribution chart, Embla Medical hf ranks #728 out of 849 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #728 out of 849 companies for Cash-to-Debt. This places Embla Medical hf in the lower half of its industry. The industry median Cash-to-Debt is 1.64. Embla Medical hf's value of 0.19 is 88.4% below this benchmark. Historically, Embla Medical hf's own Cash-to-Debt has ranged from 0.10 to 0.31 over the past decade. While the company's 10-year median is 0.18 vs. the industry median of 1.64, Embla Medical hf has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current Cash-to-Debt of 0.19 is 88.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current Cash-to-Debt is 0.19, which is near median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current Cash-to-Debt of 0.19. The stock's GF Value™ is $4.90, compared to a current price of $4.15 — trading 15.3% below its estimated fair value. The current Cash-to-Debt is 0.19, which is near median its 10-year median of 0.18 and 88.4% below the Medical Devices & Instruments industry median of 1.64. Embla Medical hf's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current Cash-to-Debt is 0.19 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 15.3% below its estimated GF Value™ of $4.90.
Key valuation signals for OSSFF:
Cash-to-Debt: 0.19 (near median its 10-year median of 0.18)
GF Value™: $4.90 vs. price of $4.15 (15.3% below fair value)
Industry Position: 88.4% below the Medical Devices & Instruments median (#728 of 849)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OSSFF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
